托珠单抗并未降低 COVID-19 住院患者的低氧性呼吸衰竭或死亡风险。
Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19.
机构信息
McMaster University, Hamilton, Ontario, Canada (S.S., B.R.).
出版信息
Ann Intern Med. 2021 Feb;174(2):JC16. doi: 10.7326/ACPJ202102160-016. Epub 2021 Feb 2.
PMID:33524280
Abstract
Stone JH, Frigault MJ, Serling-Boyd NJ, et al. N Engl J Med. 2020;383:2333-44. 33085857.
摘要
石 JH、弗里格ault MJ、塞林-博伊德 NJ 等人。《新英格兰医学杂志》。2020；383:2333-44. 33085857.
Zotero 插件